Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104

Lung cancer occurrence and associated mortality ranks top in all countries. Despite the rapid development of targeted and immune therapies, many patients experience relapse within a few years. It is urgent to uncover the mechanisms that drive lung cancer progression and identify novel molecular targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fan, Li, Ziming, Han, Qing, Cheng, Yirui, Ji, Wenxiang, Yang, Ying, Lu, Shun, Xia, Weiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176586/
https://www.ncbi.nlm.nih.gov/pubmed/32111983
http://dx.doi.org/10.1038/s41388-020-1227-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176586/
https://www.ncbi.nlm.nih.gov/pubmed/32111983
http://dx.doi.org/10.1038/s41388-020-1227-2

Ejemplares similares